Literature DB >> 17290596

Stage Ib cervical cancer during pregnancy: planned delay in treatment--case report.

K Traen1, D Svane, N Kryger-Baggesen, K Bertelsen, O Mogensen.   

Abstract

Approximately 0.05% of pregnancies are complicated with cervical cancer. Treatment of this malignancy during pregnancy depends on the stage of disease and gestational age at the time of diagnosis. In women with Stage IB cervical cancer immediate treatment, without regard to the pregnancy, is traditionally advocated in the first and second trimester. A planned delay of treatment, to achieve foetal maturity, may be acceptable if there are no adverse maternal and foetal consequences. We present a case of a Stage IB1 cervical cancer, diagnosed during a twin pregnancy, and treated with a planned delay of 19 weeks. We have reviewed the literature and focused on what is known about planned delay in therapy of Stage IB cervical cancer, diagnosed before 30 weeks of gestational age.

Entities:  

Mesh:

Year:  2006        PMID: 17290596

Source DB:  PubMed          Journal:  Eur J Gynaecol Oncol        ISSN: 0392-2936            Impact factor:   0.196


  3 in total

1.  Radical vaginal trachelectomy and laparoscopic pelvic lymphadenectomy in IB1 cervical cancer during pregnancy.

Authors:  Erasmo Bravo; Santiago Parry; Catalina Alonso; Sergio Rojas
Journal:  Gynecol Oncol Case Rep       Date:  2012-04-09

2.  Conservative treatment of uterine cervical adenocarcinoma in pregnancy.

Authors:  Cid Almeida de Lima; Ana Cristina Macêdo Barcelos; Marina de Carvalho Paschoini; João Henrique do Amaral E Silva; Marcus Aurelho de Lima; Eddie Fernando Candido Murta; Rosekeila Simões Nomelini
Journal:  Case Rep Obstet Gynecol       Date:  2013-12-17

Review 3.  Individual management of cervical cancer in pregnancy.

Authors:  Thomas Hecking; Alina Abramian; Christian Domröse; Tabea Engeln; Thore Thiesler; Claudia Leutner; Ulrich Gembruch; Mignon-Denise Keyver-Paik; Walther Kuhn; Kirsten Kübler
Journal:  Arch Gynecol Obstet       Date:  2016-01-04       Impact factor: 2.344

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.